NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

市场调查报告书

酒糟:市场洞察,流行病学,市场预测 ~2027年

Rosacea - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品编码 736690
出版日期 按订单生产 内容资讯 英文 100 Pages
商品交期: 2-10个工作天内
价格
酒糟:市场洞察,流行病学,市场预测 ~2027年 Rosacea - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 按订单生产内容资讯: 英文 100 Pages
简介

主要7个国家(美国,英国,德国,法国,义大利,西班牙,日本)的酒糟患者数在2016年为4,735万9,758人,市场规模估计为4亿9,440万美元。

本报告提供酒糟的相关调查,疾病概要,患者背景,主要7个国家性别、各种类、重症度的患病数及诊断数,各治疗药物的市场规模的变化与预测(今后10年份),已上市药及新药概要,诊断指南,市场规模,市场成长要素、障碍,竞争情形等总括性汇整。

目录

第1章 重要的洞察

第2章 酒糟:市场概要

  • 市场占有率(成果值)
  • 市场占有率(预测值)

第3章 疾病背景和概要

  • 简介
  • 征兆与症状
  • 酒糟的分类
  • 病情和重病度
  • 病理生理学
  • 全基因组相关分析(GWAS)为基础遗传的背景
  • 原因和危险因素
  • 诊断

第4章 流行病学和患者人口

  • 主要的觀察

第5章 主要7个国家的总患病数

第6章 主要7个国家的总诊断数

第7章 酒糟的流行病学:各国

  • 美国
    • 前提和根据
    • 总患病数
    • 患病数:性别
    • 总诊断数
    • 诊断数:各类型
    • 诊断数:各重症度
  • 欧洲主要5个国家
    • 德国
      • 总患病数
      • 患病数:性别
      • 总诊断数
      • 诊断数:各类型
      • 诊断数:各重症度
    • 法国
      • 总患病数
      • 患病数:性别
      • 总诊断数
      • 诊断数:各类型
      • 诊断数:各重症度
    • 义大利
      • 总患病数
      • 患病数:性别
      • 总诊断数
      • 诊断数:各类型
      • 诊断数:各重症度
    • 西班牙
      • 总患病数
      • 患病数:性别
      • 总诊断数
      • 诊断数:各类型
      • 诊断数:各重症度
    • 英国
      • 总患病数
      • 患病数:性别
      • 总诊断数
      • 诊断数:各类型
      • 诊断数:各重症度
  • 日本
    • 总患病数
    • 患病数:性别
    • 总诊断数
    • 诊断数:各类型
    • 诊断数:各重症度

第8章 治疗流程,现行治疗,医疗行为

第9章 未满足需求

第10章 已上市药

  • Rhofade:Allergan
    • 药品概要
    • 作用机制
    • 法规的里程碑
    • 产品开发趋势
    • 优点与缺点
    • 安全性和有效性
    • 产品简介
  • Oracea:Galderma Laboratories
  • Mirvaso:Galderma Laboratories
  • Finacea:Bayer
  • Soolantra:Galderma Laboratories, Inc.
  • Metrogel:Galderma Laboratories

第11章 Key Cross Competition

第12章 新药

  • FMX103:Foamix Pharmaceuticals
    • 药品概要
    • 作用机制
    • 法规的里程碑
    • 产品开发趋势
    • 优点与缺点
    • 安全性和有效性
    • 产品简介
  • Epsolay:Sol-Gel
  • Omiganan:Cutanea Life Sciences
  • BPX-04:BioPharmX, Inc.
  • ACU-D1:Accuitis., Inc.
  • HY01(Minocycline):Hovione Scientia Limited
  • DFD-04:Dr. Reddy's Laboratories
  • DFD-29:Dr. Reddy's Laboratories
  • DMT210:Dermata Therapeutics

第13章 市场分析主要7个国家

  • 主要的觀察
  • 主要7个国家的市场规模

第14章 美国市场预测

  • 美国的市场规模
    • 总市场规模
    • 市场规模:各治疗药物

第15章 市场预测欧洲5个国家

  • 德国
    • 总市场规模
    • 市场规模:各治疗药物
  • 法国
    • 总市场规模
    • 市场规模:各治疗药物
  • 义大利
    • 总市场规模
    • 市场规模:各治疗药物
  • 西班牙
    • 总市场规模
    • 市场规模:各治疗药物
  • 英国
    • 总市场规模
    • 市场规模:各治疗药物

第16章 日本市场预测

  • 总市场规模
  • 市场规模:各治疗药物

第17章 市场成长要素

第18章 市场障碍

第19章 附录

  • 调查方法

第20章 DelveInsight的服务内容

第21章 免责声明

第22章 关于DelveInsight

目录
Product Code: DIMI0199

DelveInsight's "Rosacea - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Rosacea epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Rosacea Understanding and Treatment Algorithm

The market report provides the overview of the Rosacea by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Rosacea Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Rosacea in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Rosacea Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Rosacea Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Rosacea market.

Rosacea Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Rosacea Report Insights

  • Patient Population in Rosacea
  • Therapeutic Approaches in Rosacea
  • Rosacea Pipeline Analysis
  • Rosacea Market Size and Trends
  • Rosacea Market Opportunities
  • Impact of upcoming Therapies in Rosacea

Rosacea Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Rosacea Report Assessment

  • Current Treatment Practices in Rosacea
  • Unmet Needs in Rosacea
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Rosacea market
  • Organize sales and marketing efforts by identifying the best opportunities for Rosacea market
  • To understand the future market competition in the Rosacea market.

Table of Contents

1. Report Introduction

2. Rosacea Market Overview at a Glance

  • 2.1. Market Share Distribution of Rosacea in 2016
  • 2.2. Market Share Distribution of Rosacea in 2028

3. Disease Background and Overview: Rosacea

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Rosacea in 7MM
  • 4.3. Total Prevalent Patient Population of Rosacea in 7MM - By Countries

5. Epidemiology of Rosacea by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Rosacea
    • 5.1.3. Sub-Type Specific cases of the Rosacea *
    • 5.1.4. Sex- Specific Cases of the Rosacea *
    • 5.1.5. Diagnosed Cases of the Rosacea
    • 5.1.6. Treatable Cases of the Rosacea
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Rosacea
    • 5.4.3. Sub-Type Specific cases of the Rosacea *
    • 5.4.4. Sex- Specific Cases of the Rosacea *
    • 5.4.5. Diagnosed Cases of the Rosacea
    • 5.4.6. Treatable Cases of the Rosacea
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Rosacea
    • 5.5.3. Sub-Type Specific cases of the Rosacea *
    • 5.5.4. Sex- Specific Cases of the Rosacea *
    • 5.5.5. Diagnosed Cases of the Rosacea
    • 5.5.6. Treatable Cases of the Rosacea
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Rosacea
    • 5.6.3. Sub-Type Specific cases of the Rosacea *
    • 5.6.4. Sex- Specific Cases of the Rosacea *
    • 5.6.5. Diagnosed Cases of the Rosacea
    • 5.6.6. Treatable Cases of the Rosacea
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Rosacea
    • 5.7.3. Sub-Type Specific cases of the Rosacea *
    • 5.7.4. Sex- Specific Cases of the Rosacea *
    • 5.7.5. Diagnosed Cases of the Rosacea
    • 5.7.6. Treatable Cases of the Rosacea
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Rosacea
    • 5.8.3. Sub-Type Specific cases of the Rosacea *
    • 5.8.4. Sex- Specific Cases of the Rosacea *
    • 5.8.5. Diagnosed Cases of the Rosacea
    • 5.8.6. Treatable Cases of the Rosacea
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Rosacea
    • 5.9.3. Sub-Type Specific cases of the Rosacea *
    • 5.9.4. Sex- Specific Cases of the Rosacea *
    • 5.9.5. Diagnosed Cases of the Rosacea
    • 5.9.6. Treatable Cases of the Rosacea

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Rosacea

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Rosacea

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Rosacea : 7MM Market Analysis

  • 12.1. 7MM Market Size of Rosacea
  • 12.2. 7MM Percentage Share of drugs marketed for Rosacea
  • 12.3. 7MM Market Sales of Rosacea by Products

13. Rosacea : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Rosacea in United States
    • 13.1.2. Percentage Share of drugs marketed for Rosacea in United States
    • 13.1.3. Market Sales of Rosacea by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Rosacea in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Rosacea in Germany
      • 13.2.1.3. Market Sales of Rosacea by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Rosacea in France
      • 13.2.2.2. Percentage Share of drugs marketed for Rosacea in France
      • 13.2.2.3. Market Sales of Rosacea by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Rosacea in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Rosacea in Italy
      • 13.2.3.3. Market Sales of Rosacea by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Rosacea in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Rosacea in Spain
      • 13.2.4.3. Market Sales of Rosacea by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Rosacea in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Rosacea in United Kingdom
      • 13.2.5.3. Market Sales of Rosacea by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Rosacea in Japan
    • 13.3.2. Percentage Share of drugs marketed for Rosacea in Japan
    • 13.3.3. Market Sales of Rosacea by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Table 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Table 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Table 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Table 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Table 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Table 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Table 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Table 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Table 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Table 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Table 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Table 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Table 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Table 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Table 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Table 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Figure 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Figure 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Figure 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)